I
Immune-Onc Therapeutics
Developing a novel class of myeloid checkpoint inhibitors
About Immune-Onc Therapeutics
Immune-Onc Therapeutics is a clinical-stage startup operating in the healthcare sector, specifically in the field of cancer immunotherapy. The company is pioneering a new class of treatments known as myeloid checkpoint inhibitors, which are believed to be the next big thing in cancer immunotherapy. These inhibitors work by targeting immune suppressive pathways, potentially transforming the current treatment approaches for both blood cancers and solid tumors.
Read full description
Immune-Onc's business model revolves around research and development, with a focus on creating a portfolio of these novel inhibitors. The company collaborates with scientists, academic institutions, and non-profit cancer organizations to discover and develop new immunomodulatory approaches to cancer treatment. Their clients are primarily patients suffering from various types of cancer who could benefit from immunotherapy.
The company operates in the biopharmaceutical market, a sector characterized by high research and development costs, long product development cycles, and a complex regulatory environment. Immune-Onc generates revenue through the development and eventual commercialization of its innovative cancer treatments. The company's efforts are supported by investors with significant industry experience, who are committed to making the company's vision a reality for patients.
At a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Palo Alto, United States
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 65.5/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Immune-Onc Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Jan 2023 | $25M | $365M | The Leukemia & Lymphoma Society · Proxima Ventures · WuXi Biologics · TriWise Capital | ↗ |
| SERIES BOther financing | Apr 2021 | $73M | $292M | NLVC · The Leukemia & Lymphoma Society · Sphera Funds Management · Vivo Capital | — |
Growth signals
Latest recorded traffic for Immune-Onc Therapeutics is 2.6K monthly website visits, up 44.4% over the last three months. Immune-Onc Therapeutics's team declined 13.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
National Cancer Institute (NCI)
Small Business Innovation Research
Series A11 investors entered at this stage
CLI Ventures
Loyal Valley Capital
NLVC
Vivo Capital
The Leukemia & Lymphoma Society
Sphera Funds Management
Octagon Capital Partners
Oceanpine Capital
Proxima Ventures
WuXi Biologics- TCTriWise Capital
Other known investors1 additional known investor
- TSThe University of Texas Southwestern Medical School
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Immune-Onc Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Immune-Onc Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.